Drug efficacy and selectivity assessed in patient-derived bone marrow and blood samples, preserving the native hematopoietic microenvironment.

Functional testing of anticancer drugs in tumor-aligned 3D cultures that replicate spatial and immune features of the tumor microenvironment.

Patient-derived immune cells used to study functional response and drug-induced modulation under physiological conditions.

Ex vivo assays to detect hematologic toxicity and on-target off-tumor effects in physiologically relevant environments, including for ADCs and immunotherapies.

Genomic, transcriptomic and epigenetic profiling to identify drug mechanisms, predictive biomarkers and stratification strategies in preclinical studies.

Multimodal data integration combining functional assays and omics profiles to support translational research and drug development decisions.

Ethically sourced samples from hematologic malignancies, solid tumors and autoimmune diseases with associated clinical and molecular data.

Correlation of functional drug response with molecular signatures to support biomarker identification and CDx development in precision medicine.